Want to see IN:ENTERO full AI Analyst Report?
ENTERO Stock Chart & Stats
₹1230.80
₹43.80(3.56%)
At close: 4:00 PM EDT
₹1230.80
₹43.80(3.56%)
Day’s Range― - ―
52-Week Range₹944.00 - ₹1,390.00
Previous CloseN/A
Volume165.84K
Average Volume (3M)6.57K
Market Cap
₹54.17B
Enterprise Value₹58.72K
Total Cash (Recent Filing)₹2.92B
Total Debt (Recent Filing)₹6.77B
Price to Earnings (P/E)47.0
Beta0.69
Next Earnings
Aug 07, 2026EPS Estimate
6.8Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)26.44
Shares Outstanding43,523,070
10 Day Avg. Volume6,792
30 Day Avg. Volume6,572
Financial Highlights & Ratios
PEG Ratio2.22
Price to Book (P/B)3.22
Price to Sales (P/S)0.82
P/FCF Ratio3.05K
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹1,500.00Price Target Upside21.87% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)40
Revenue Forecast (FY)₹81.09B
Bulls Say, Bears Say
Bulls Say
Sustained Revenue GrowthEntero's multiyear revenue expansion demonstrates durable scale gains in pharmaceutical distribution. Growing top line supports bargaining power with suppliers, better fixed-cost absorption and route density benefits, enabling sustainable margin improvement potential as operations scale.
Return To ProfitabilityThe shift from multi-year losses to positive net income in FY2026 indicates improved unit economics and operational leverage. Consistent profitability, if maintained, permits reinvestment, gradual deleveraging and building cash reserves to support long-term growth initiatives.
Equity Base And Moderate LeverageA sizable equity base and a moderate D/E ratio provide financial cushion to absorb shocks and fund strategic investments. This balance sheet footing supports working-capital financing needs and measured capital expenditures without immediate pressure to restructure operations.
Bears Say
Weak Cash ConversionPersistently weak cash conversion—OCF negative until FY2026 and near-zero FCF—signals working-capital intensity and limited internal funding capacity. Low cash generation constrains reinvestment, makes the business reliant on external financing, and raises refinancing risk over time.
Thin And Compressed MarginsDeclining gross margin and very thin net margins expose Entero to supplier pricing shifts and competitive pressure. Limited margin headroom reduces resilience to cost inflation or adverse commercial terms and constrains the ability to generate meaningful cash from profits.
Rising LeverageIncreasing debt levels alongside weak cash conversion raise financial risk. Higher leverage reduces flexibility for strategic spending, increases interest and covenant sensitivity, and magnifies the impact of any operational setbacks on solvency and credit access.
Entero Healthcare Solutions Limited News
ENTERO FAQ
What was Entero Healthcare Solutions Limited’s price range in the past 12 months?
Entero Healthcare Solutions Limited lowest stock price was ₹944.00 and its highest was ₹1390.00 in the past 12 months.
What is Entero Healthcare Solutions Limited’s market cap?
Entero Healthcare Solutions Limited’s market cap is ₹54.17B.
When is Entero Healthcare Solutions Limited’s upcoming earnings report date?
Entero Healthcare Solutions Limited’s upcoming earnings report date is Aug 07, 2026 which is in 3 days.
How were Entero Healthcare Solutions Limited’s earnings last quarter?
Entero Healthcare Solutions Limited released its earnings results on May 25, 2026. The company reported ₹6.4 earnings per share for the quarter, missing the consensus estimate of ₹9.1 by -₹2.7.
Is Entero Healthcare Solutions Limited overvalued?
According to Wall Street analysts Entero Healthcare Solutions Limited’s price is currently Undervalued.
Does Entero Healthcare Solutions Limited pay dividends?
Entero Healthcare Solutions Limited does not currently pay dividends.
What is Entero Healthcare Solutions Limited’s EPS estimate?
Entero Healthcare Solutions Limited’s EPS estimate is 6.8.
How many shares outstanding does Entero Healthcare Solutions Limited have?
Entero Healthcare Solutions Limited has 43,523,070 shares outstanding.
What happened to Entero Healthcare Solutions Limited’s price movement after its last earnings report?
Entero Healthcare Solutions Limited reported an EPS of ₹6.4 in its last earnings report, missing expectations of ₹9.1. Following the earnings report the stock price went up 0.085%.
Which hedge fund is a major shareholder of Entero Healthcare Solutions Limited?
Currently, no hedge funds are holding shares in IN:ENTERO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Entero Healthcare Solutions Limited
Established in 2018 and headquartered in Mumbai, India, Entero Healthcare Solutions Limited functions as a key distributor within the Indian healthcare sector. The company specializes in supplying a diverse range of medical and health-related products, including pharmaceuticals, surgical instruments, medical equipment, over-the-counter remedies, nutritional supplements, and vaccines. Its extensive client base spans retail pharmacies, hospitals, nursing homes, and various healthcare clinics throughout the country.
ENTERO Stock 12 Month Forecast
Average Price Target
₹1,500.00
▲(21.87% Upside)
Technical Analysis
Artemis Medicare Services Ltd.
―
Bliss Gvs Pharma Limited
―
Orchid Pharma Limited
―
RPG Life Sciences Limited
―
Unichem Laboratories Limited
―